SCHEMBL687882

SCHEMBL687882

CC(C)CCCCCCCCCCCCCCC/C(C(=O)O)=C(\CCCCCCCCCCCCCCCC(C)C)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 2/20 0.50
KDM4A O75164 1/20 0.50
PHF8 Q9UPP1 1/20 0.50
KDM2A Q9Y2K7 1/20 0.50
FNTA P49354 4/20 0.45
FNTB P49356 4/20 0.45
THRB P10828 1/20 0.45
PGGT1B P53609 1/20 0.45
BLM P54132 1/20 0.42
FFAR4 Q5NUL3 1/20 0.39
FFAR1 O14842 1/20 0.39
CA1 P00915 2/20 0.39
LMNA P02545 1/20 0.39
LTA4H P09960 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
DEGS1 O15121 1/20 0.37
KDM1A O60341 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3824075 1.00 KDM4C (0.50) KDM4CKDM4APHF8KDM2AFNTA
SCHEMBL2148740 1.00 KDM4C (0.50) KDM4CKDM4APHF8KDM2AFNTA
SCHEMBL2904418 1.00 KDM4C (0.50) KDM4CKDM4APHF8KDM2AFNTA
SCHEMBL5720556 1.00 KDM4C (0.50) KDM4CKDM4APHF8KDM2AFNTA
SCHEMBL1053609 1.00 KDM4C (0.50) KDM4CKDM4APHF8KDM2AFNTA
SCHEMBL5720596 1.00 KDM4C (0.50) KDM4CKDM4APHF8KDM2AFNTA
SCHEMBL689111 1.00 KDM4C (0.50) KDM4CKDM4APHF8KDM2AFNTA
SCHEMBL690967 1.00 KDM4C (0.50) KDM4CKDM4APHF8KDM2AFNTA
SCHEMBL690966 1.00 KDM4C (0.50) KDM4CKDM4APHF8KDM2AFNTA
SCHEMBL14672444 1.00 KDM4C (0.50) KDM4CKDM4APHF8KDM2AFNTA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210275408-A1 STICK-TYPE SHEET MASK AND MANUFACTURING METHOD THEREFOR JANG YUN HEE (KR) 2021-09-09 US claimed
US-20070122508-A1 Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease HELIXIR CO., LTD. (KR) 2007-05-31 US claimed
US-12616730-B2 Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof MEDIHELPLINE CO., LTD (KR) 2026-05-05 US disclosed
US-20240130952-A1 REACTIVE TOPICAL SKIN PROTECTANT FORMULATIONS FOR THE PROTECTION AGAINST SKIN PENETRATION OF LIQUID CHEMICAL AGENTS OR HARMFUL TOXIC SUBSTANCES Agency for Defense Developement (KR) 2024-04-25 US disclosed
US-20230127213-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE TREATMENT OR ALLEVIATION OF SKIN ULCER AND THE USE THEREOF PARK, OK NAM (KR) 2023-04-27 US disclosed
US-20230103514-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE SKIN REGENERATION AND THE TREATMENT OR ALLEVIATION OF SKIN WOUND AND THE USE THEREOF MEDIHELPLINE CO., LTD (KR) 2023-04-06 US disclosed
US-20230100173-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR TLSP INHIBITION AND THE TREATMENT OR ALLEVIATION OF SKIN INFLAMMATORY DISEASE AND THE USE THEREOF MEDIHELPLINE CO., LTD (KR) 2023-03-30 US disclosed
EP-4117698-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE SKIN REGENERATION AND THE TREATMENT OR ALLEVIATION OF SKIN WOUND AND THE USE THEREOF Medihelpline Co., Ltd. (KR) 2023-01-18 EP disclosed
EP-4117699-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR THE TREATMENT OR ALLEVIATION OF SKIN ULCER AND THE USE THEREOF Medihelpline Co., Ltd. (KR) 2023-01-18 EP disclosed
EP-4117700-A1 A TOPICAL COMPOSITION COMPRISING AN EXTRACT OF COMBINED HERBS COMPRISING LONGANAE ARILLUS FOR TLSP INHIBITION AND THE TREATMENT OR ALLEVIATION OF SKIN INFLAMMATORY DISEASE AND THE USE THEREOF Medihelpline Co., Ltd. (KR) 2023-01-18 EP disclosed
CN-115297879-A Topical composition comprising arillus longan combined crude drug extract for regenerating skin and treating or improving skin wound, and its application (株)美迪合伙来音 2022-11-04 CN disclosed
WO-2006093793-A2 COMPOSITIONS COMPRISING ACTINIDIA AND METHODS OF USE THEREOF EFFICAS, INC. (US) 2006-09-08 WO disclosed
WO-2006090939-A1 COSMETIC COMPOSITION COMPRISING BETA-FRUCTOSYL-L-ASCORBIC ACID FOR SKIN WHITENING BIOLAND LTD. (KR) 2006-08-31 WO disclosed
WO-2006016728-A1 COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA FOR PREVENTING AND TREATING BALDNESS DISORDERS AND SEBORRHEIC SKIN DISORDERS HELIXIR CO., LTD. (KR) 2006-02-16 WO disclosed
EP-1551433-A1 COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA AND RELATED SPECIES FOR THE PREVENTION AND TREATMENT OF ALLERGIC DISEASE AND NON-ALLERGIC INFLAMMATORY DISEASE Pangenomics Co., Ltd. (KR) 2005-07-13 EP disclosed
WO-2004096171-A1 SKIN WHITENING COSMETIC COMPOSITION COMPRISING THE EXTRACT OF MACHILUS THUNBERGII AND THE COMPOUNDS ISOLATED THEREFROM YEUNGNAM EDUCATIONAL FOUNDATION (KR) 2004-11-11 WO disclosed
WO-2004017982-A1 COMPOSITION COMPRISING THE EXTRACT OF ACTINIDIA ARGUTA AND RELATED SPECIES FOR THE PREVENTION AND TREATMENT OF ALLERGIC DISEASE AND NON-ALLERGIC INFLAMMATORY DISEASE PANGENOMICS CO., LTD (KR) 2004-03-04 WO disclosed
US-20040037909-A1 Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease VIROMED CO., LTD. (KR) 2004-02-26 US disclosed
US-20030202948-A1 O/W emulsion WACKER-CHEMIE GMBH (DE) 2003-10-30 US disclosed
EP-0332501-B1 Use of polyacrylate polymers as stabilizing agents of dispersions constituted of a water-insoluble phase in an aqueous phase, dispersions obtained, and their preparation PAYOT N G LAB (FR) 1994-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12616730-B2 Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof CUTA, VEGFA, MMP8 KDM4C 3167/4885KDM4A 3295/4885PHF8 935/4885
US-20240130952-A1 REACTIVE TOPICAL SKIN PROTECTANT FORMULATIONS FOR THE PROTECTION AGAINST SKIN PENETRATION OF LIQUID CHEMICAL AGENTS OR HARMFUL TOXIC SUBSTANCES CUTA, FIBP, DSG1 KDM4C 3349/4885KDM4A 3748/4885PHF8 961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.